Sanofi Canada is committed to supporting patients who have recently been prescribed SARCLISA® for relapsed and/or refractory multiple myeloma.1
The REACH™ Patient Support Program provides eligible patients with services like medication administration, reimbursement or financial assistance, and education.
Medication
Administration
REACH™ acts as the single point of contact between healthcare professionals and patients, facilitating seamless patient access to SARCLISA® treatment in Bayshore clinics through nurse coordination and facilitation.
Reimbursement or Financial Assistance
REACH™ provides expert advice in pursuing insurance reimbursement in a timely manner. Sanofi Canada may provide financial support.
Education
REACH™ provides patients with treatment education materials before their first dose. The entire REACH™ nursing staff has completed pharmacovigilance and SARCLISA®-specific training as well as chemotherapy/biotherapy validation.